Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARCELLX, INC.

71.31
+1.041.48%
Post-market: 71.310.00000.00%16:20 EDT
Volume:339.89K
Turnover:24.09M
Market Cap:3.93B
PE:-23.79
High:71.57
Open:70.69
Low:69.51
Close:70.27
Loading ...

Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment

TIPRANKS
·
18 Jul

We're Not Very Worried About Arcellx's (NASDAQ:ACLX) Cash Burn Rate

Simply Wall St.
·
11 Jul

Piper Sandler Reaffirms Their Buy Rating on Arcellx Inc (ACLX)

TIPRANKS
·
08 Jul

Arcellx Shares up 1.9% After Citigroup Initiates Coverage With Buy Rating

THOMSON REUTERS
·
17 Jun

Arcellx Initiated at Buy by Citigroup

Dow Jones
·
17 Jun

Arcellx Shares up 2.7% Premarket After Citigroup Initiates Coverage With Buy Rating

THOMSON REUTERS
·
17 Jun

Citigroup Initiates Arcellx at Buy With $110 Price Target

MT Newswires Live
·
17 Jun

Arcellx initiated with a Buy at Citi

TIPRANKS
·
17 Jun

Arcellx Price Target Maintained With a $115.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Jun

Barclays Keeps Their Buy Rating on Arcellx Inc (ACLX)

TIPRANKS
·
04 Jun

Arcellx Inc. CFO Michelle Gilson Reports Disposal of Common Shares

Reuters
·
29 May

Arcellx Inc. Conducted Annual Stockholders Meeting

Reuters
·
29 May

Arcellx Announces Its Participation at TD Cowen’s 6TH Annual Oncology Innovation Summit and Its Investor Event During Eha2025

THOMSON REUTERS
·
22 May

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
19 May

Stock Track | Arcellx Plummets 5.14% Despite Announcing Positive Study Data, Raising Market Concerns

Stock Track
·
16 May

Stock Track | Arcellx Plummets 5.14% Despite Announcing Positive Study Data, Raising Market Concerns

Stock Track
·
14 May

Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise

MT Newswires Live
·
14 May

Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel

TIPRANKS
·
14 May

Stock Track | Arcellx (ACLX) Soars 5.56% on Positive Data from Multiple Myeloma Study

Stock Track
·
14 May

Arcellx Announces New Positive Data for Its Immagine-1 Study in Patients With Relapsed and/or Refractory Multiple Myeloma

THOMSON REUTERS
·
14 May